about
Designing drugs to avoid toxicity2 Heterosteroids and Drug ResearchCombinatorial chemistry as a tool for drug discovery.Virtual screening of virtual libraries.Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases.Progress in the development of beta-secretase inhibitors for Alzheimer's disease.Modern view of vitamin D3 and its medicinal uses.Neurokinin receptor antagonists.Opioid receptor antagonists.Mechanisms of bacterial resistance to antibiotics and biocides.Towards cannabinoid drugs--revisited.Influenza virus sialidase: a target for drug discovery.Fibrinogen receptor antagonists: design and clinical applications.New directions in anxiolytic drug research.Selective inhibitors of cyclooxygenase-2 (COX-2).Molecularly imprinted polymers--preparation, biomedical applications and technical challenges.CCK-B antagonists in the control of anxiety and gastric acid secretion.Application of high-throughput screening techniques to drug discovery.Development of neurosteroid-based novel psychotropic drugs.Benzo[b]pyranols and related novel antiepileptic agents.The discovery and development of atorvastatin, a potent novel hypolipidemic agent.Molecular modeling of opioid receptor-ligand complexes.Antimicrobial activity and action of silver.Biological activity of polyene antibiotics.The mechanism of action of some antibacterial agents.Small molecule bromodomain inhibitors: extending the druggable genome.The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS.p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines.The medicinal chemistry of the P2 receptor family.Radioligands for the study of brain 5-HT1A receptors in vivo.Discovery of montelukast: a once-a-day oral antagonist of leukotriene D4 for the treatment of chronic asthma.The histamine H3 receptor and its ligands.Isothermal titration calorimetry in drug discovery.The adenosine A3 receptor and its ligands.Copper complexes offer a physiological approach to treatment of chronic diseases.Lonidamine and related compounds.5-HT2C ligands: recent progress.Heterosteroids and drug research.Clinically useful chelators of tripositive elements.Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases.
P1433
Q28305269-10C8BDB5-F06E-4575-84A2-D5417E58EFF5Q29027271-F91194E5-916C-4AC5-BBA7-3C6F61CED3BFQ30872244-80CDF70A-A842-44F8-9131-B0DE3DCF35A1Q30939415-7F2DD648-62DB-47BC-94BF-89D046231A2EQ33819023-DB8CC22C-3E17-4AE9-A53B-3FA6BB003AA7Q33890347-9BF9C49D-6277-417C-B2EC-5B997B012E5AQ33905985-C8B5CF71-4F7E-4C91-B765-53EA9515FEEBQ33905991-B676F20F-2BB6-4064-9072-96D634FBB4D5Q33905996-574D6DCF-C2CB-4F67-8EF5-521788EB5C3EQ33906001-E7B5DDD4-A459-4085-BC6C-860B8C94F17CQ33906007-E1AC740D-FC7A-48A6-8BCA-8E5E4575E8D7Q33922846-466274B6-D794-4887-A4C1-8830AE38FD0EQ33922853-04872A8D-4167-4A07-A8B2-59E1BC280CC8Q33922860-DCFF64F2-4742-4CAE-8FE3-A0F1D86D34A7Q33922865-5EF9A08D-12BE-4483-847F-3ED7EB2A7EECQ33922869-32A31FE0-BCAD-4737-9FAF-1CD949BDA65EQ33938906-0EF6662B-D7A3-459A-8B66-9C33F7BFA513Q33938910-00FA8912-85B7-4924-872A-BE8B93DA4125Q33938916-F9C0373A-A418-4D58-843A-21695E9E1073Q33938920-A5CC79A3-F106-41F6-A7F2-4D51B3501E33Q33963546-EB2A8162-6325-40AF-912B-F1344313FEE5Q33963552-995EDF1F-355C-4BA9-AAF1-3EEA67CF076BQ34060064-1D4C0EBE-DE83-4786-9A93-5529B454FDF7Q34179545-27DCE609-CF5F-4E68-8DF1-AE07651916D3Q34206212-6C7EA2BD-560B-40EC-8DEF-25CEA6FE310BQ34240674-9E0690EE-6732-40FC-80DE-9A93CB4034E2Q34413630-046132A3-B7CF-48E9-AE16-497417A39EA7Q34483284-42A1EBF0-C8AF-42EA-B7EB-5FEF7977262DQ34483289-9F027876-FB30-461B-8537-E5ECAA8C8564Q34483298-410655F5-FD03-446D-A832-3E52BD708EC3Q34483306-69019FD8-F077-4FC7-AD36-DDF625083DC8Q34483311-F5B60A01-AECB-486A-8F12-9EE79DD82FF3Q34483315-BA6EEA99-36CA-4191-AB39-A123BF8CD3FBQ34483322-DE9713E3-B526-4E7D-9E08-1F57AFECB162Q34515066-F78EF7C7-9103-4683-ABE4-303D605238D7Q34709229-AF182CBC-8A60-42A4-AA94-1351E5B7C8D4Q34766538-2A829C31-3B9D-4B30-BADA-2FB7F9E3A0A4Q34774023-EAD8C230-B6D7-4F90-AB5E-0C6D9169B796Q34774041-E8425C42-1C60-44E7-A222-92B2E032E166Q35040174-B59A518B-4F3F-4387-B130-265E8FB2BFD1
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Elsevier
@nl
wissenschaftliche Fachzeitschrift
@de
name
Progress in medicinal chemistry
@ast
Progress in medicinal chemistry
@en
Progress in medicinal chemistry
@es
Progress in medicinal chemistry
@it
Progress in medicinal chemistry
@nl
type
label
Progress in medicinal chemistry
@ast
Progress in medicinal chemistry
@en
Progress in medicinal chemistry
@es
Progress in medicinal chemistry
@it
Progress in medicinal chemistry
@nl
altLabel
Prog Med Chem
@en
prefLabel
Progress in medicinal chemistry
@ast
Progress in medicinal chemistry
@en
Progress in medicinal chemistry
@es
Progress in medicinal chemistry
@it
Progress in medicinal chemistry
@nl
P1055
P1156
P123
P1277
P1476
Progress in medicinal chemistry
@en